Hikal Limited (IN:HIKAL)
:HIKAL
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹456.60
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹21.57B
Enterprise Value₹28.51B
Total Cash (Recent Filing)₹340.00M
Total Debt (Recent Filing)₹7.20B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jun 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)1.80
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio1.79
Price to Book (P/B)3.92
Price to Sales (P/S)2.66
P/FCF Ratio34.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.3
Revenue Forecast (FY)₹18.66B
Bulls Say, Bears Say
Bulls Say
High Gross And Improving MarginsSustained high gross margins and improving EBITDA/net margins indicate durable pricing power and manufacturing efficiency in specialty chemicals. This margin profile supports long-term cash generation, funds reinvestment in R&D and capacity, and cushions against raw-material volatility over the next several quarters.
Strong Cash GenerationRobust free cash flow and a 3.09 OCF-to-net-income ratio demonstrate high cash conversion quality. Reliable cash generation underpins capex and working-capital needs, reduces reliance on external financing, and provides a durable buffer for cyclical downturns or to pursue CDMO contract opportunities.
Moderate Leverage And Healthy Equity RatioA moderate debt-to-equity ratio and near 50% equity ratio suggest a conservative capital structure with financial flexibility. Combined with improving ROE, this supports sustainable investment in capacity and R&D while keeping interest burden manageable, strengthening long-term resilience.
Bears Say
Inconsistent Revenue GrowthVolatile top-line undermines predictability and prevents full leverage of fixed manufacturing capacity. Inconsistent revenue makes forward planning harder, can depress utilisation-sensitive margins, and raises execution risk for multi-quarter growth targets in CDMO and agro segments.
Sharp EPS VolatilityVery negative EPS growth signals earnings volatility or one-off shocks that weaken near-term profitability trends. Large swings in reported earnings reduce stakeholder confidence, constrain reinvestment decisions, and may limit management's ability to sustainably expand dividends or pursue capital-intensive projects.
Concentration In Cyclical End-marketsDependence on pharmaceutical and crop-protection demand exposes Hikal to regulatory cycles, product approvals, and agricultural seasonality. Such end-market cyclicality can cause material swings in order volumes and utilization, pressuring margins and cash flow consistency over multi-quarter horizons.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹456.60 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹21.57B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Jun 18, 2026 which is in 69 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Feb 11, 2026. The company reported ₹1.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.8.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.8 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹1.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.977%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―